$9.8 Billion in Federal Fraud Settlements. Zero Executives in Prison.

The complete federal fraud settlement record for illegal marketing of psychiatric medications, 1996-2014.

We have been researching the intersection of pharmaceutical marketing and psychiatric diagnosis for the last year while building clinical monitoring tools. The pattern we found was not subtle. Every major manufacturer of atypical antipsychotics and several major antidepressant makers paid federal fraud settlements for illegal marketing of psychiatric drugs. Not some of them. All of them. Here is the documented record, sourced entirely to Department of Justice press releases, federal court filings, and Congressional investigation records.

The Scoreboard

| Company | Drug | Settlement | Year | Criminal Plea | Drug Lifetime Revenue | |---------|------|-----------|------|---------------|----------------------| | GlaxoSmithKline | Paxil, Wellbutrin, Avandia | $3 billion | 2012 | Guilty, 3 counts | $11.7B (Paxil US, 1997-2006) | | Pfizer | Geodon (+ Bextra, others) | $2.3 billion total | 2009 | Felony (Bextra) | N/A | | Johnson and Johnson | Risperdal, Invega, Natrecor | $2.2 billion | 2013 | Misdemeanor | $30B+ (Risperdal lifetime) | | Abbott Laboratories | Depakote | $1.5 billion (+ $100M to states) | 2012 | Misdemeanor | N/A | | Eli Lilly | Zyprexa | $1.415 billion | 2009 | Misdemeanor | $39B+ (Zyprexa lifetime) | | AstraZeneca | Seroquel | $520 million (+ $68.5M to states) | 2010 | Civil (no criminal) | N/A | | Bristol-Myers Squibb | Abilify | $515 million (+ $19.5M to states) | 2007 | Civil | N/A | | Forest Laboratories | Celexa, Lexapro | $313 million | 2010 | Felony + misdemeanor | N/A | | Shire | Adderall XR, Vyvanse | $56.5 million | 2014 | N/A | N/A |

Combined federal settlements: over $9.8 billion.

Combined lifetime revenue of the drugs involved, where publicly documented: over $100 billion.

Penalties as a percentage of revenue: 2-5%.

Every case was initiated or advanced by whistleblower qui tam lawsuits under the False Claims Act.

No senior pharmaceutical executive served prison time in any of these cases.

GlaxoSmithKline: $3 Billion (2012)

The largest healthcare fraud settlement in United States history at the time of filing.

GSK pleaded guilty to three criminal counts, including two counts of introducing misbranded drugs (Paxil and Wellbutrin) into interstate commerce and one count of failing to report safety data about Avandia to the FDA.

For Paxil specifically, GSK promoted the drug for use in patients under 18 despite the FDA never approving it for pediatric use. The promotion was built in part on Study 329, a clinical trial of paroxetine (Paxil) in 275 adolescents with major depression. The study failed all eight of its prespecified primary efficacy endpoints. An internal GSK memo from October 1998 stated that it would be "commercially unacceptable to include a statement that efficacy had not been demonstrated." GSK hired a medical communications firm (Scientific Therapeutics Information) to ghost-write the published manuscript. The paper, published in the Journal of the American Academy of Child and Adolescent Psychiatry in 2001 with Brown University psychiatrist Martin Keller listed as lead author, concluded that paroxetine was "generally well tolerated and effective" for adolescent depression. The ghost-writer, Sally K. Laden, was credited only for "editorial assistance."

The published paper obscured serious adverse events. Of 93 patients on paroxetine, 11 experienced serious adverse events. Five involved suicidal ideation or self-harm, classified in the paper under the vague category "emotional lability." GSK had conducted two additional negative pediatric trials (Studies 377 and 701) and chose not to publish either one.

After Study 329 was published, Paxil became the number one prescribed antidepressant in the United States, with $340 million in sales by end of 2001. Pediatric prescriptions reached 2.1 million in 2002. A 2015 reanalysis published in the BMJ by Le Noury, Jureidini, and Healy, using the original clinical study reports obtained through legal discovery, concluded that paroxetine showed no efficacy advantage over placebo and was associated with increased harms in adolescents. The original paper has never been retracted.

GSK also promoted Wellbutrin for weight loss and sexual dysfunction, uses never approved by the FDA.

Source: DOJ press release, July 2, 2012. BMJ 2015;351:h4320.

Johnson and Johnson: $2.2 Billion (2013)

J&J's subsidiary Janssen Pharmaceuticals promoted Risperdal (risperidone) for use in elderly dementia patients and children, populations for which the drug was not approved.

J&J created a specialized "ElderCare" sales force of 83 to 136 representatives targeting nursing homes and long-term care facilities. The FDA had warned Janssen in 1999 that marketing presentations focused on elderly dementia patients were misleading. J&J continued the promotion. The company also paid millions in kickbacks to Omnicare, the nation's largest nursing home pharmacy, which J&J internally referred to as "an extension of its sales force."

For pediatric promotion, J&J funded the Johnson and Johnson Center for Pediatric Psychopathology at Massachusetts General Hospital with at least $700,000. Internal documents revealed during litigation showed that the center was created to "generate and disseminate data supporting the use of risperidone in this patient population." The center's own annual report stated it would "move forward the commercial goals of J&J." The center was led by Harvard psychiatrist Joseph Biederman.

Senator Charles Grassley's 2008 investigation found that Biederman and two colleagues (Thomas Spencer and Timothy Wilens) had received a combined $4.2 million from drug manufacturers between 2000 and 2007, while disclosing only a fraction of that income to Harvard as required. In one year alone (2001), J&J paid Biederman $58,169 while he initially reported $0 to Harvard.

During the period of Biederman's most active promotion of pediatric bipolar disorder as a diagnosis, pediatric bipolar diagnoses in US outpatient settings increased 40-fold between 1994 and 2003, from 25 to 1,003 per 100,000 youth visits, according to Moreno et al. in Archives of General Psychiatry (2007).

Separately, over 13,000 individual lawsuits alleged that Risperdal caused gynecomastia (breast tissue growth) in boys and young men. One jury awarded $8 billion in punitive damages, later reduced by a judge to $6.8 million. J&J settled approximately 9,000 remaining gynecomastia cases for roughly $800 million in 2021.

Risperdal's lifetime global sales exceeded $30 billion.

Source: DOJ press release, November 4, 2013. HHS OIG enforcement records.

Eli Lilly: $1.415 Billion (2009)

Eli Lilly promoted Zyprexa (olanzapine) for use in elderly dementia patients and for conditions including depression, anxiety, and sleep disturbance, none of which were FDA-approved uses.

Lilly's own internal data revealed significant safety concerns that were not adequately communicated to prescribers. A 1995 internal expert panel found that Zyprexa produced average weight gain of 24 pounds per year, with 1 in 6 patients gaining over 66 pounds. A February 2000 internal document showed patients on Zyprexa were 3.5 times more likely to develop high blood sugar compared to a competitor drug. Neither finding was fully submitted to the FDA.

In October 2000, Lilly launched the "Viva Zyprexa" campaign targeting primary care physicians who had no specialized training in antipsychotic prescribing. The campaign used the "5 at 5" slogan, promoting 5 milligrams of Zyprexa at 5 PM as a sleep aid. This reframed the drug's primary side effect (sedation) as a therapeutic benefit and pushed an antipsychotic into a primary care context for a non-psychotic indication.

In March 2002, Lilly rejected internal plans to give psychiatrists diabetes screening guidance. An internal memo stated that providing such guidance "would further build its association to Zyprexa."

Alex Berenson's December 2006 investigation in the New York Times, based on hundreds of leaked internal Lilly documents, exposed the decade-long pattern of data suppression. Zyprexa's cumulative global sales exceeded $39 billion. The $1.415 billion settlement represented approximately 3.6% of that revenue. Lilly additionally paid $1.2 billion to settle more than 28,000 individual product-liability lawsuits.

Source: DOJ press release, January 15, 2009. New York Times, December 17, 2006.

Abbott Laboratories: $1.5 Billion (2012)

Abbott illegally promoted Depakote (divalproex sodium) for the control of agitation and aggression in elderly dementia patients in nursing homes, and for use in schizophrenia, despite FDA approval only for epilepsy, bipolar mania, and migraine prevention.

Abbott maintained a specialized long-term care sales force that targeted nursing homes. Abbott sales representatives promoted Depakote as a chemical restraint for managing difficult behavior in elderly patients, a use with no evidence of efficacy and significant safety risks including liver damage.

Source: DOJ records, 2012.

AstraZeneca: $520 Million (2010)

AstraZeneca promoted Seroquel (quetiapine) for uses not approved by the FDA, including insomnia, anxiety, anger management, and ADHD. The company targeted primary care physicians, pediatricians, and the correctional system with these off-label promotion efforts.

AstraZeneca also paid kickbacks to physicians to induce them to prescribe Seroquel, including payments for lectures and publications for which the company controlled the content.

Source: DOJ records, 2010.

Forest Laboratories: $313 Million (2010)

Forest pleaded guilty to one felony count and one misdemeanor count related to its promotion of Celexa (citalopram) for pediatric use and its distribution of the unapproved drug Levothroid.

Forest promoted Celexa for depression in children and adolescents from 1998 to 2005 despite FDA approval only for adult major depressive disorder. Critically, Forest had conducted a European clinical trial of Celexa in children that showed the drug was no more effective than placebo and was associated with higher rates of suicidal thinking. Forest suppressed these results while promoting supposedly positive findings from a separate study.

Internal documents included a quote from a Forest Regulatory Affairs Manager: "Part of my job is to create 'masterful' euphemisms to protect Medical and Marketing."

Source: DOJ press release, September 15, 2010.

Shire: $56.5 Million (2014)

Shire promoted Adderall XR, Vyvanse, and other ADHD drugs with claims that the medications could "normalize" patients with ADHD and make them "indistinguishable from non-ADHD peers." These claims were not supported by clinical evidence.

Shire also claimed its drugs could prevent poor academic performance, job loss, criminal behavior, car accidents, and divorce, with no scientific evidence supporting any of these claims.

The ADHD medication market grew from $759 million in 2000 to $3.1 billion by 2004. The $56.5 million settlement represented a fraction of the market expansion these promotional claims helped drive.

Source: DOJ/USAO Eastern District of Pennsylvania, September 2014.

The Pattern

Each case followed the same structure. A psychiatric drug is approved by the FDA for a specific, narrow indication. The manufacturer promotes it for broader, unapproved uses because broader use means larger markets. Key opinion leaders at academic medical centers are paid to lend credibility to the expanded uses. Negative clinical trial data is suppressed or reframed. Sales forces are created to target populations (elderly, children, primary care patients) where prescribers have less psychiatric training and less ability to critically evaluate the claims. When the illegal marketing is eventually discovered, the settlement is paid from a small fraction of the revenue the illegal marketing generated. No executives go to prison. The drug remains on the market.

This pattern was not limited to one company or one drug. It was the business model of the entire sector during this period.

What Happened Next

Senator Charles Grassley's investigations between 2004 and 2012, which exposed the undisclosed pharmaceutical payments to researchers like Biederman and Charles Nemeroff at Emory University, directly produced the Physician Payments Sunshine Act. Enacted in 2010 as part of the Affordable Care Act and implemented in 2013, the Sunshine Act requires pharmaceutical and medical device manufacturers to report all payments over $10 to physicians through the CMS Open Payments database.

Since implementation, the database has recorded over 88 million transactions totaling $76.9 billion in payments from manufacturers to physicians.

ProPublica's analysis of this data confirmed that physicians who receive pharmaceutical industry payments prescribe more brand-name drugs. For 46 of the 50 top brand-name medications, paid physicians wrote more prescriptions than unpaid physicians.

The settlements are a matter of public record. The DOJ press releases are available online. The court documents are available online. The pharmaceutical industry's relationship to psychiatric diagnosis and treatment during this period is documented in federal filings, not speculation.

These are the facts.